Figures and Tables

From the following article:

Cancer-related anemia and recombinant human erythropoietin—an updated overview

Julia Bohlius, Olaf Weingart, Sven Trelle and Andreas Engert

Nature Clinical Practice Oncology (2006) 3, 152-164
doi:10.1038/ncponc0451

BACK TO ARTICLE
Figure 2 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.com

Figure 2

Meta-analysis of the relative risk to receive red blood cell transfusions for cancer patients receiving erythropoietin or standard care

Full size and legend (73K)Download PowerPoint slide (277K)
Table 1 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.com

Table 1

Grading of anemia according to the National Cancer Institute classification

Full size and legend Download PowerPoint slide (230K)
Table 2 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.com

Table 2

Effect of recombinant human erythropoietin on hemoglobin response and transfusion rates: FDA license indication studies

Full size and legend Download PowerPoint slide (292K)
Table 3 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.com

Table 3

Effect of recombinant human erythropoietin on hemoglobin response and transfusion rates in randomized controlled trials including published data on >200 patients

Full size and legend Download PowerPoint slide (466K)
BACK TO ARTICLE